# Safety And Efficacy Of Bosutinib

> **NCT02501330** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 702 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT02501330
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-01
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 702 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501330, "Safety And Efficacy Of Bosutinib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02501330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*